117 related articles for article (PubMed ID: 34455227)
1. Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review.
Sun X; Wang X; Zhang J; Zhao Z; Feng X; Liu L; Ma Z
Breast; 2021 Dec; 60():26-34. PubMed ID: 34455227
[TBL] [Abstract][Full Text] [Related]
2. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
Chao Z; Wang Z; Li L; Jiang Y; Tang Y; Wang Y; Hao X; Zhang C; Guo X; Yu W; Cheng F; Wang Z
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138301
[No Abstract] [Full Text] [Related]
4. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Cheng H; Yang J; Liu H; Xiang Y
Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Wei Y; He L; Liu T; Guo T; Xie C; Jia J; Lin Y; Liu J; Fan J
Front Pharmacol; 2024; 15():1372077. PubMed ID: 38584601
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis.
Olivares-Hernández A; Roldán-Ruiz J; Miramontes-González JP; Toribio-García I; García-Hernández JL; Posado-Domínguez L; Bellido-Hernández L; Cruz-Hernández JJ; Fonseca-Sánchez E; Del Barco-Morillo E
Chin Clin Oncol; 2023 Dec; 12(6):62. PubMed ID: 38195073
[TBL] [Abstract][Full Text] [Related]
7. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
Zhou S; Jiang Y; Luo C; Yuan L
Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
[TBL] [Abstract][Full Text] [Related]
8. High Poly(ADP-Ribose) Polymerase Expression Does Relate to Poor Survival in Solid Cancers: A Systematic Review and Meta-Analysis.
Thakur N; Yim K; Abdul-Ghafar J; Seo KJ; Chong Y
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830749
[TBL] [Abstract][Full Text] [Related]
9. A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Gao W; Muston D; Monberg M; McLaurin K; Hettle R; Szamreta E; Swallow E; Zhang S; Kalemaj I; Signorovitch J; McQueen RB
Pharmacoeconomics; 2020 Nov; 38(11):1201-1218. PubMed ID: 32794041
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials.
Mustafa MT; Abushanab AK; Mousa MT; Qawaqzeh RA; Alakhras HM; Othman AS; Sa'ed A
Expert Rev Anticancer Ther; 2024; 24(1-2):71-79. PubMed ID: 38252024
[TBL] [Abstract][Full Text] [Related]
11. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Corbaux P; You B; Glasspool RM; Yanaihara N; Tinker AV; Lindemann K; Ray-Coquard IL; Mirza MR; Subtil F; Colomban O; Péron J; Karamouza E; McNeish I; Kelly C; Kagimura T; Welch S; Lewsley LA; Paoletti X; Cook A
Eur J Cancer; 2023 Sep; 191():112966. PubMed ID: 37542936
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutation profiling in
Kwong A; Cheuk IW; Shin VY; Ho CY; Au CH; Ho DN; Wong EY; Yu SW; Chen J; Chan KK; Ngan HY; Chan TL; Ma ES
Am J Cancer Res; 2020; 10(9):2919-2932. PubMed ID: 33042626
[TBL] [Abstract][Full Text] [Related]
13. Durable response to first-line PARP inhibition in
Smith JT; Sama S; Florou V; Nevala-Plagemann C; Garrido-Laguna I
J Gastrointest Oncol; 2023 Dec; 14(6):2637-2643. PubMed ID: 38196540
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety.
Jia X; Wang K; Zhuo Q; Zhao Z; Li M
Clin Breast Cancer; 2024 Mar; ():. PubMed ID: 38580572
[TBL] [Abstract][Full Text] [Related]
15. Association of BRCA mutation status with the efficacy of poly (ADP-ribose) polymerase inhibitors in cancer: A systematic review and meta-analysis.
Wang S; Xu H; Ai J; Yang L
Asian J Surg; 2023 Dec; 46(12):5473-5474. PubMed ID: 37541880
[No Abstract] [Full Text] [Related]
16. Outcomes of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer progressed after prior poly (adenosine diphosphate-ribose) polymerase inhibitors: A retrospective cohort study.
Zhao Y; Yuan H; Chen Y; Yao H; Li N; Wu L; Yuan G
Eur J Surg Oncol; 2024 May; 50(7):108383. PubMed ID: 38704898
[TBL] [Abstract][Full Text] [Related]
17. Treatment Options for Germline
Grzelak D
J Adv Pract Oncol; 2021 Jul; 12(5):488-491. PubMed ID: 34430059
[TBL] [Abstract][Full Text] [Related]
18. ABC4 Consensus: Assessment by a German Group of Experts.
Harbeck N; Lüftner D; Marschner N; Untch M; Augustin D; Briest S; Ettl J; Haidinger R; Müller L; Müller V; Ruckhäberle E; Wuerstlein R; Thomssen C
Breast Care (Basel); 2018 Mar; 13(1):48-58. PubMed ID: 29950968
[TBL] [Abstract][Full Text] [Related]
19. Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
Maiorano BA; De Giorgi U; Verzoni E; Maiello E; Procopio G; Conteduca V; Di Maio M;
Target Oncol; 2024 Jan; 19(1):127. PubMed ID: 38070004
[No Abstract] [Full Text] [Related]
20. Site-agnostic PARP-inhibitor maintenance therapy of advanced stage
Tostrud LJ; Somasegar S; Renz M
Gynecol Oncol Rep; 2024 Jun; 53():101406. PubMed ID: 38736717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
